443 related articles for article (PubMed ID: 12860943)
1. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
Taplin ME; Rajeshkumar B; Halabi S; Werner CP; Woda BA; Picus J; Stadler W; Hayes DF; Kantoff PW; Vogelzang NJ; Small EJ;
J Clin Oncol; 2003 Jul; 21(14):2673-8. PubMed ID: 12860943
[TBL] [Abstract][Full Text] [Related]
2. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
4. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.
Suzuki H; Akakura K; Komiya A; Aida S; Akimoto S; Shimazaki J
Prostate; 1996 Sep; 29(3):153-8. PubMed ID: 8827083
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
6. [Antiandrogen withdrawal syndrome].
Akimoto S
Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
[TBL] [Abstract][Full Text] [Related]
7. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
[TBL] [Abstract][Full Text] [Related]
8. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor gene mutations in hormone-refractory prostate cancer.
Wallén MJ; Linja M; Kaartinen K; Schleutker J; Visakorpi T
J Pathol; 1999 Dec; 189(4):559-63. PubMed ID: 10629558
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
Taplin ME; Bubley GJ; Shuster TD; Frantz ME; Spooner AE; Ogata GK; Keer HN; Balk SP
N Engl J Med; 1995 May; 332(21):1393-8. PubMed ID: 7723794
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
[TBL] [Abstract][Full Text] [Related]
12. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.
Tilley WD; Buchanan G; Hickey TE; Bentel JM
Clin Cancer Res; 1996 Feb; 2(2):277-85. PubMed ID: 9816170
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression.
Salah Z; Maoz M; Cohen I; Pizov G; Pode D; Runge MS; Bar-Shavit R
FASEB J; 2005 Jan; 19(1):62-72. PubMed ID: 15629896
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Jewett MA; Emami M; Vesprini D; Chu W; Ho M; Sweet J; Evans A; Toi A; Pollak M; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1429-37. PubMed ID: 14693733
[TBL] [Abstract][Full Text] [Related]
17. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.
Gaddipati JP; McLeod DG; Heidenberg HB; Sesterhenn IA; Finger MJ; Moul JW; Srivastava S
Cancer Res; 1994 Jun; 54(11):2861-4. PubMed ID: 8187068
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
Palmberg C; Koivisto P; Hyytinen E; Isola J; Visakorpi T; Kallioniemi OP; Tammela T
Eur Urol; 1997; 31(2):216-9. PubMed ID: 9076469
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.
Hsing AW; Gao YT; Wu G; Wang X; Deng J; Chen YL; Sesterhenn IA; Mostofi FK; Benichou J; Chang C
Cancer Res; 2000 Sep; 60(18):5111-6. PubMed ID: 11016637
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
